T-cell costimulation blockade with abatacept for acute GvHD: Results of the ABA2 trial
There are still no approved agents for preventing severe acute (a) graft-versus-host disease (GvHD), which is a major cause of non-relapse mortality (NRM).
FDA accepts a supplemental new drug application for ruxolitinib in steroid-refractory cGvHD
On February 22, 2021, the U.S. Food and Drug Administration (FDA) granted priority review to a supplemental new drug application (sNDA) for ruxolitinib for...
"The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information."